Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.
AstraZeneca and the health services organization Geisinger have partnered to improve asthma care by creating a suite of products that integrate into the electronic health record.
Physicians and health plan executives agree that healthcare has made little progress toward value-based care since last year, according to a survey by Quest Diagnostics.
The U.S. Justice Department joined several whistleblower lawsuits against Indivior and Reckitt Benckiser Group, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.
Intouch Solutions announced the hires of Paula Hackl, vice president of business transformations; Machelle Henks, vice president of strategic planning; Mendy McGuire, PharmD, vice president of medical strategy; and Mike Yonker, vice president of consulting and technology strategy in the firm’s Kansas City office.
INSYS Therapeutics Inc. announced today that the company reached an agreement in principle with the Department of Justice to settle the DOJ’s civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.
Anthony Tartaglia, a technology executive with vast experience in consumer and healthcare brands, has been added to Razorfish Health’s leadership team as SVP, Digital Solutions.
The FDA approved Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor) to include use in children ages 2-5 years with cystic fibrosis who have two copies of the F508del-CFTR mutation.
Akouos, a precision genetic medicine company developing gene therapies that restore and preserve hearing, today announced that the company raised $50 million in Series A financing.
August 06, 2018 07:30 ET | Source: VIVUS, Inc. CAMPBELL, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) — VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced […]
